自体脂肪移植作为乳房重建方式的肿瘤学安全性:单中心乳腺癌复发率与手术结局回顾
脂肪移植组与对照组局部复发率相似(2.5%对1.9%,p=0.747),且脂肪移植组复发时间显著更长(52.3个月对22.8个月,p=0.016),支持其肿瘤学安全性。
要点
- 脂肪移植组局部复发率2.5%,对照组1.9%,差异无统计学意义(p=0.747)。
- 脂肪移植组平均复发时间52.3个月,显著长于对照组22.8个月(p=0.016)。
- 脂肪移植总体并发症率为9.4%,多数患者仅接受1次移植(83.1%)。
核心结论
- 自体脂肪移植是乳房重建的有力工具,本单中心大样本研究为其肿瘤学安全性提供了循证支持。
主要发现
- 脂肪移植组与对照组体重指数、吸烟状态及BRCA状态相似,但脂肪移植组更年轻且糖尿病、高血压、高脂血症更少。
- 脂肪移植组83.1%接受1次手术,13.7%接受2次,2.8%接受3次,0.4%接受4次。
- 脂肪移植组平均随访45.6个月,对照组38.8个月;脂肪移植总体并发症率9.4%。
- 治疗性指征手术中,脂肪移植组局部复发率2.5%,对照组1.9%(p=0.747)。
- 脂肪移植组平均复发时间52.3个月,显著长于对照组22.8个月(p=0.016)。
临床怎么用
- 在乳房切除后重建中可考虑自体脂肪移植,现有证据未显示局部复发风险增加。
局限性
- 单中心回顾性设计,证据等级为治疗性III级,随访时间有限,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing use of autologous fat grafting in breast cancer patients has raised concerns regarding its oncologic safety. This study evaluated patient outcomes and tumor recurrence following mastectomy reconstruction and autologous fat grafting. METHODS: Retrospective chart review identified patients who underwent mastectomy followed by breast reconstruction from 2010 to 2015. Eight hundred twenty-nine breasts met inclusion criteria: 248 (30.0 percent) underwent autologous fat grafting, whereas 581 (70.0 percent) breasts did not. Patient demographics, cancer characteristics, oncologic treatment, surgical treatment, surgical complications, local recurrence, and distant metastases were analyzed. RESULTS: Autologous fat grafting patients and control patients were of similar body mass index, smoking status, and BRCA status. Patients who underwent fat grafting were significantly younger than control patients and were less likely to have diabetes, hypertension, or hyperlipidemia. The two groups represented similar distributions of BRCA status, Oncotype scores, and hormone receptor status. Patients underwent one to four grafting procedures: one procedure in 83.1 percent, two procedures in 13.7 percent, three in 2.8 percent, and four in 0.4 percent. Mean follow-up time from initial surgery was 45.6 months in the fat grafting group and 38.8 months in controls. The overall complication rate following fat grafting was 9.4 percent. Among breasts undergoing surgery for therapeutic indications, there were similar rates of local recurrence (fat grafting group, 2.5 percent; controls, 1.9 percent; p = 0.747). Interestingly, mean time to recurrence was significantly longer in the fat grafting group (52.3 months versus 22.8 months from initial surgery; p = 0.016). CONCLUSIONS: Autologous fat grafting is a powerful tool in breast reconstruction. This large, single-institution study provides valuable evidence-based support for its oncologic safety. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Cohen O, Lam G, Karp N, et al. Determining the Oncologic Safety of Autologous Fat Grafting as a Reconstructive Modality: An Institutional Review of Breast Cancer Recurrence Rates and Surgical Outcomes. Plast Reconstr Surg. 2017. PMID: 28841600. doi:10.1097/PRS.0000000000003576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。